-
1
-
-
0023205953
-
Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin
-
Herold, K. C., Montag, A. G & Fitch, F. W. Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin. Diabetes 36, 796-801 (1987).
-
(1987)
Diabetes
, vol.36
, pp. 796-801
-
-
Herold, K.C.1
Montag, A.G.2
Fitch, F.W.3
-
2
-
-
0017179001
-
Streptozotocin-induced pancreatic insulitis: New model of diabetes mellitus
-
Like, A. A. & Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415-417 (1976).
-
(1976)
Science
, vol.193
, pp. 415-417
-
-
Like, A.A.1
Rossini, A.A.2
-
3
-
-
0018565284
-
Spontaneous diabetes mellitus: Reversal and prevention in the BB/W rat with antiserum to rat lymphocytes
-
Like, A. A., Rossini, A. A., Guberski, D. L., Appel, M. C. & Williams, R. M. Spontaneous diabetes mellitus: reversal and prevention in the BB/W rat with antiserum to rat lymphocytes. Science 206, 1421-1423 (1979).
-
(1979)
Science
, vol.206
, pp. 1421-1423
-
-
Like, A.A.1
Rossini, A.A.2
Guberski, D.L.3
Appel, M.C.4
Williams, R.M.5
-
4
-
-
23844525846
-
A comprehensive review of interventions in the NOD mouse and implications for translation
-
Shoda, L. K. et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23, 115-126 (2005).
-
(2005)
Immunity
, vol.23
, pp. 115-126
-
-
Shoda, L.K.1
-
5
-
-
27144475336
-
Type 1 diabetes genes and pathways shared by humans and NOD mice
-
Wicker, L. S. et al. Type 1 diabetes genes and pathways shared by humans and NOD mice. J. Autoimmun. 25 (Suppl.), 29-33 (2005).
-
(2005)
J. Autoimmun.
, vol.25
, pp. 29-33
-
-
Wicker, L.S.1
-
6
-
-
34249032122
-
Are insights gained from NOD mice sufficient to guide clinical translation Another inconvenient truth
-
Roep, B. O. Are insights gained from NOD mice sufficient to guide clinical translation Another inconvenient truth. Ann. NY Acad. Sci. 1103, 1-10 (2007).
-
(2007)
Ann. NY Acad. Sci.
, vol.1103
, pp. 1-10
-
-
Roep, B.O.1
-
7
-
-
78049423506
-
An update on the use of NOD mice to study autoimmune (type 1) diabetes
-
Chaparro, R. J. & Dilorenzo, T. P. An update on the use of NOD mice to study autoimmune (type 1) diabetes. Expert Rev. Clin. Immunol. 6, 939-955 (2010).
-
(2010)
Expert Rev. Clin. Immunol.
, vol.6
, pp. 939-955
-
-
Chaparro, R.J.1
Dilorenzo, T.P.2
-
8
-
-
77955756080
-
Use of nonobese diabetic mice to understand human type 1 diabetes
-
Thayer, T. C., Wilson, S. B. & Mathews, C. E. Use of nonobese diabetic mice to understand human type 1 diabetes. Endocrinol. Metab. Clin. North Am. 39, 541-561 (2010).
-
(2010)
Endocrinol. Metab. Clin. North Am.
, vol.39
, pp. 541-561
-
-
Thayer, T.C.1
Wilson, S.B.2
Mathews, C.E.3
-
9
-
-
79251621206
-
Mouse models for the study of autoimmune type 1 diabetes: A NOD to similarities and differences to human disease
-
Driver, J. P., Serreze, D. V. & Chen, Y. G. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin. Immunopathol. 33, 67-87 (2011).
-
(2011)
Semin. Immunopathol.
, vol.33
, pp. 67-87
-
-
Driver, J.P.1
Serreze, D.V.2
Chen, Y.G.3
-
10
-
-
78751662679
-
Type 1 diabetes: Etiology, immunology, and therapeutic strategies
-
van Belle, T. L., Coppieters, K. T. & von Herrath, M. G. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 91, 79-118 (2011).
-
(2011)
Physiol. Rev.
, vol.91
, pp. 79-118
-
-
Van Belle, T.L.1
Coppieters, K.T.2
Von Herrath, M.G.3
-
11
-
-
84879532718
-
Comparative genetics: Synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes
-
Driver, J. P., Chen, Y. G. & Mathews, C. E. Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes. Rev. Diabet. Stud. 9, 169-187 (2012).
-
(2012)
Rev. Diabet. Stud.
, vol.9
, pp. 169-187
-
-
Driver, J.P.1
Chen, Y.G.2
Mathews, C.E.3
-
12
-
-
84860845827
-
The use of animal models in diabetes research
-
King, A. J. The use of animal models in diabetes research. Br. J. Pharmacol. 166, 877-894 (2012).
-
(2012)
Br. J. Pharmacol.
, vol.166
, pp. 877-894
-
-
King, A.J.1
-
13
-
-
84930791607
-
Insulitis in human type 1 diabetes: A comparison between patients and animal models
-
In't Veld, P. Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin. Immunopathol. 36, 569-579 (2014).
-
(2014)
Semin. Immunopathol.
, vol.36
, pp. 569-579
-
-
In'T Veld, P.1
-
14
-
-
84885080249
-
Advances in our understanding of the pathophysiology of type 1 diabetes: Lessons from the NOD mouse
-
Jayasimhan, A., Mansour, K. P. & Slattery, R. M. Advances in our understanding of the pathophysiology of type 1 diabetes: lessons from the NOD mouse. Clin. Sci. (Lond.) 126, 1-18 (2014).
-
(2014)
Clin. Sci. (Lond.)
, vol.126
, pp. 1-18
-
-
Jayasimhan, A.1
Mansour, K.P.2
Slattery, R.M.3
-
15
-
-
0018841766
-
Breeding of a non-obese, diabetic strain of mice
-
Makino, S. et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29, 1-13 (1980).
-
(1980)
Jikken Dobutsu
, vol.29
, pp. 1-13
-
-
Makino, S.1
-
16
-
-
0021929456
-
Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus
-
Assan, R. et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1, 67-71 (1985).
-
(1985)
Lancet
, vol.1
, pp. 67-71
-
-
Assan, R.1
-
17
-
-
0025049497
-
Limited duration of remission of insulin dependency in children with recent overt type i diabetes treated with low-dose cyclosporin
-
Bougnères, P. F. et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39, 1264-1272 (1990).
-
(1990)
Diabetes
, vol.39
, pp. 1264-1272
-
-
Bougnères, P.F.1
-
18
-
-
0026629806
-
Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus
-
Jenner, M., Bradish, G., Stiller, C. & Atkison, P. Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus. London Diabetes Study Group. Diabetologia 35, 884-888 (1992).
-
(1992)
London Diabetes Study Group. Diabetologia
, vol.35
, pp. 884-888
-
-
Jenner, M.1
Bradish, G.2
Stiller, C.3
Atkison, P.4
-
19
-
-
0022353991
-
Increase in remission rate in newly diagnosed type i diabetic subjects treated with azathioprine
-
Harrison, L. C., Colman, P. G., Dean, B., Baxter, R. & Martin, F. I. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 34, 1306-1308 (1985).
-
(1985)
Diabetes
, vol.34
, pp. 1306-1308
-
-
Harrison, L.C.1
Colman, P.G.2
Dean, B.3
Baxter, R.4
Martin, F.I.5
-
20
-
-
0024813410
-
Double-blind controlled trial of azathioprine in children with newly diagnosed type i diabetes
-
Cook, J. J. et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 38, 779-783 (1989).
-
(1989)
Diabetes
, vol.38
, pp. 779-783
-
-
Cook, J.J.1
-
21
-
-
0023735943
-
Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus
-
Silverstein, J. et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319, 599-604 (1988).
-
(1988)
N. Engl. J. Med.
, vol.319
, pp. 599-604
-
-
Silverstein, J.1
-
22
-
-
0037198420
-
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
-
Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
-
(2002)
N. Engl. J. Med.
, vol.346
, pp. 1692-1698
-
-
Herold, K.C.1
-
23
-
-
20044375937
-
A single course of anti-CD3 monoclonal antibody hOKT31(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
-
Herold, K. C. et al. A single course of anti-CD3 monoclonal antibody hOKT31(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54, 1763-1769 (2005).
-
(2005)
Diabetes
, vol.54
, pp. 1763-1769
-
-
Herold, K.C.1
-
24
-
-
84887052291
-
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders
-
Herold, K. C. et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62, 3766-3774 (2013).
-
(2013)
Diabetes
, vol.62
, pp. 3766-3774
-
-
Herold, K.C.1
-
25
-
-
70449480577
-
Rituximab B-lymphocyte depletion, and preservation of-cell function
-
Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion, and preservation of-cell function. N. Engl. J. Med. 361, 2143-2152 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 2143-2152
-
-
Pescovitz, M.D.1
-
26
-
-
84887621720
-
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
-
Rigby, M. R. et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 1, 284-294 (2013).
-
(2013)
Lancet Diabetes Endocrinol.
, vol.1
, pp. 284-294
-
-
Rigby, M.R.1
-
27
-
-
79960912796
-
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial
-
Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412-419 (2011).
-
(2011)
Lancet
, vol.378
, pp. 412-419
-
-
Orban, T.1
-
28
-
-
84897851090
-
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year after cessation of treatment
-
Orban, T. et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37, 1069-1075 (2014).
-
(2014)
Diabetes Care
, vol.37
, pp. 1069-1075
-
-
Orban, T.1
-
29
-
-
84865478468
-
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs-cell function
-
Long, S. A. et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs-cell function. Diabetes 61, 2340-2348 (2012).
-
(2012)
Diabetes
, vol.61
, pp. 2340-2348
-
-
Long, S.A.1
-
30
-
-
0025837184
-
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin
-
Zhang, Z. J., Davidson, L., Eisenbarth, G. S. & Weiner, H. L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl Acad. Sci. USA 88, 10252-10256 (1991).
-
(1991)
Proc. Natl Acad. Sci. USA
, vol.88
, pp. 10252-10256
-
-
Zhang, Z.J.1
Davidson, L.2
Eisenbarth, G.S.3
Weiner, H.L.4
-
31
-
-
0028861576
-
Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-transcription
-
Muir, A. et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-transcription. J. Clin. Invest. 95, 628-634 (1995).
-
(1995)
J. Clin. Invest.
, vol.95
, pp. 628-634
-
-
Muir, A.1
-
32
-
-
16144361909
-
Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice
-
Tian, J. et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat. Med. 2, 1348-1353 (1996).
-
(1996)
Nat. Med.
, vol.2
, pp. 1348-1353
-
-
Tian, J.1
-
33
-
-
0031831753
-
Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice
-
Tisch, R., Liblau, R. S., Yang, X. D., Liblau, P. & McDevitt, H. O. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 47, 894-899 (1998).
-
(1998)
Diabetes
, vol.47
, pp. 894-899
-
-
Tisch, R.1
Liblau, R.S.2
Yang, X.D.3
Liblau, P.4
McDevitt, H.O.5
-
34
-
-
84881374695
-
The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes
-
Boettler, T. et al. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. J. Autoimmun. 44, 40-48 (2013).
-
(2013)
J. Autoimmun.
, vol.44
, pp. 40-48
-
-
Boettler, T.1
-
35
-
-
67650685905
-
Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice
-
Suarez-Pinzon, W. L., Cembrowski, G. S. & Rabinovitch, A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52, 1680-1682 (2009).
-
(2009)
Diabetologia
, vol.52
, pp. 1680-1682
-
-
Suarez-Pinzon, W.L.1
Cembrowski, G.S.2
Rabinovitch, A.3
-
36
-
-
0037106362
-
Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice
-
Drage, M. et al. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice. Transplantation 74, 611-619 (2002).
-
(2002)
Transplantation
, vol.74
, pp. 611-619
-
-
Drage, M.1
-
37
-
-
0027365946
-
Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival
-
Sandberg, J. O., Eizirik, D. L., Sandler, S., Tracey, D. E. & Andersson, A. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 42, 1845-1851 (1993).
-
(1993)
Diabetes
, vol.42
, pp. 1845-1851
-
-
Sandberg, J.O.1
Eizirik, D.L.2
Sandler, S.3
Tracey, D.E.4
Andersson, A.5
-
38
-
-
0030920680
-
IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice
-
Sandberg, J. O., Eizirik, D. L. & Sandler, S. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 108, 314-317 (1997).
-
(1997)
Clin. Exp. Immunol.
, vol.108
, pp. 314-317
-
-
Sandberg, J.O.1
Eizirik, D.L.2
Sandler, S.3
-
39
-
-
0041376742
-
Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents
-
Gysemans, C. et al. Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents. Diabetologia 46, 1115-1123 (2003).
-
(2003)
Diabetologia
, vol.46
, pp. 1115-1123
-
-
Gysemans, C.1
-
40
-
-
40749153195
-
Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation
-
Simon, G. et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57, 405-414 (2008).
-
(2008)
Diabetes
, vol.57
, pp. 405-414
-
-
Simon, G.1
-
41
-
-
0033846982
-
No effect of oral insulin on residual-cell function in recent-onset type i diabetes (the IMDIAB VII)
-
Pozzilli, P. et al. No effect of oral insulin on residual-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43, 1000-1004 (2000).
-
(2000)
IMDIAB Group. Diabetologia
, vol.43
, pp. 1000-1004
-
-
Pozzilli, P.1
-
42
-
-
0037198427
-
Effects of insulin in relatives of patients with type 1 diabetes mellitus
-
Diabetes Prevention Trial-Type 1 Diabetes Study Group
-
Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685-1691 (2002).
-
(2002)
N. Engl. J. Med.
, vol.346
, pp. 1685-1691
-
-
-
43
-
-
84856564903
-
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
-
Ludvigsson, J. et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 366, 433-442 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 433-442
-
-
Ludvigsson, J.1
-
44
-
-
84908347082
-
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial
-
Griffin, K. J., Thompson, P. A., Gottschalk, M., Kyllo, J. H. & Rabinovitch, A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet 2, 710-718 (2014).
-
(2014)
Lancet
, vol.2
, pp. 710-718
-
-
Griffin, K.J.1
Thompson, P.A.2
Gottschalk, M.3
Kyllo, J.H.4
Rabinovitch, A.5
-
45
-
-
80055084799
-
Preliminary studies related to anti-interleukin-1 therapy in children with newly diagnosed type 1 diabetes
-
Sumpter, K. M., Adhikari, S., Grishman, E. K. & White, P. C. Preliminary studies related to anti-interleukin-1 therapy in children with newly diagnosed type 1 diabetes. Pediatr. Diabetes 12, 656-667 (2011).
-
(2011)
Pediatr. Diabetes
, vol.12
, pp. 656-667
-
-
Sumpter, K.M.1
Adhikari, S.2
Grishman, E.K.3
White, P.C.4
-
46
-
-
84878300647
-
Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials
-
Moran, A. et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381, 1905-1915 (2013).
-
(2013)
Lancet
, vol.381
, pp. 1905-1915
-
-
Moran, A.1
-
47
-
-
84887624109
-
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial
-
Gitelman, S. E. et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 1, 306-316 (2013).
-
(2013)
Lancet Diabetes Endocrinol.
, vol.1
, pp. 306-316
-
-
Gitelman, S.E.1
-
48
-
-
0024457594
-
Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes
-
Hayward, A. R. & Shreiber, M. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J. Immunol. 143, 1555-1559 (1989).
-
(1989)
J. Immunol.
, vol.143
, pp. 1555-1559
-
-
Hayward, A.R.1
Shreiber, M.2
-
49
-
-
0026546211
-
Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody
-
Herold, K. C. et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41, 385-391 (1992).
-
(1992)
Diabetes
, vol.41
, pp. 385-391
-
-
Herold, K.C.1
-
50
-
-
0026580049
-
Reduced incidence of insulitis in NOD mice following anti-CD3 injection: Requirement for neonatal injection
-
Hayward, A. R. & Shreiber, M. Reduced incidence of insulitis in NOD mice following anti-CD3 injection: requirement for neonatal injection. J. Autoimmun. 5, 59-67 (1992).
-
(1992)
J. Autoimmun.
, vol.5
, pp. 59-67
-
-
Hayward, A.R.1
Shreiber, M.2
-
51
-
-
0027958044
-
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
-
Chatenoud, L., Thervet, E., Primo, J. & Bach, J. F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 91, 123-127 (1994).
-
(1994)
Proc. Natl Acad. Sci. USA
, vol.91
, pp. 123-127
-
-
Chatenoud, L.1
Thervet, E.2
Primo, J.3
Bach, J.F.4
-
52
-
-
0031569177
-
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
-
Chatenoud, L., Primo, J. & Bach, J. F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158, 2947-2954 (1997).
-
(1997)
J. Immunol.
, vol.158
, pp. 2947-2954
-
-
Chatenoud, L.1
Primo, J.2
Bach, J.F.3
-
53
-
-
36849027817
-
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
-
Hu, C. Y. et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857-3867 (2007).
-
(2007)
J. Clin. Invest.
, vol.117
, pp. 3857-3867
-
-
Hu, C.Y.1
-
54
-
-
43049171493
-
B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in FcR effector functions
-
Xiu, Y. et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in FcR effector functions. J. Immunol. 180, 2863-2875 (2008).
-
(2008)
J. Immunol.
, vol.180
, pp. 2863-2875
-
-
Xiu, Y.1
-
55
-
-
20544443927
-
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
-
Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005).
-
(2005)
N. Engl. J. Med.
, vol.352
, pp. 2598-2608
-
-
Keymeulen, B.1
-
56
-
-
84908218494
-
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes
-
Aronson, R. et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37, 2746-2754 (2014).
-
(2014)
Diabetes Care
, vol.37
, pp. 2746-2754
-
-
Aronson, R.1
-
57
-
-
84896116224
-
Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study
-
Ambery, P. et al. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet. Med. 31, 399-402 (2014).
-
(2014)
Diabet. Med.
, vol.31
, pp. 399-402
-
-
Ambery, P.1
-
58
-
-
0035032076
-
Enhanced survival of grafts genetically endowed with the ability to block CD2 and B7
-
Brady, J. L., Yamashita, K. & Lew, A. M. Enhanced survival of grafts genetically endowed with the ability to block CD2 and B7. Cell Transplant. 10, 175-181 (2001).
-
(2001)
Cell Transplant.
, vol.10
, pp. 175-181
-
-
Brady, J.L.1
Yamashita, K.2
Lew, A.M.3
-
59
-
-
0242574700
-
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
-
Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
-
(2003)
N. Engl. J. Med.
, vol.349
, pp. 1907-1915
-
-
Kremer, J.M.1
-
60
-
-
23644455857
-
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
-
Kremer, J. M. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 2263-2271 (2005).
-
(2005)
Arthritis Rheum.
, vol.52
, pp. 2263-2271
-
-
Kremer, J.M.1
-
61
-
-
16044371193
-
CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes
-
Lenschow, D. J. et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5, 285-293 (1996).
-
(1996)
Immunity
, vol.5
, pp. 285-293
-
-
Lenschow, D.J.1
-
62
-
-
0028900297
-
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
-
Lenschow, D. J. et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, 1145-1155 (1995).
-
(1995)
J. Exp. Med.
, vol.181
, pp. 1145-1155
-
-
Lenschow, D.J.1
-
63
-
-
0036314243
-
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice
-
Rabinovitch, A., Suarez-Pinzon, W. L., Shapiro, A. M., Rajotte, R. V. & Power, R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51, 638-645 (2002).
-
(2002)
Diabetes
, vol.51
, pp. 638-645
-
-
Rabinovitch, A.1
Suarez-Pinzon, W.L.2
Shapiro, A.M.3
Rajotte, R.V.4
Power, R.5
-
64
-
-
1342303482
-
Of mice and not men: Differences between mouse and human immunology
-
Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004).
-
(2004)
J. Immunol.
, vol.172
, pp. 2731-2738
-
-
Mestas, J.1
Hughes, C.C.2
-
65
-
-
84904261048
-
New insights into disease-specific absence of complement factor H related protein C in mouse models of spontaneous autoimmune diseases
-
Mehta, G., Ferreira, V. P., Skerka, C., Zipfel, P. F. & Banda, N. K. New insights into disease-specific absence of complement factor H related protein C in mouse models of spontaneous autoimmune diseases. Mol. Immunol. 62, 235-248 (2014).
-
(2014)
Mol. Immunol.
, vol.62
, pp. 235-248
-
-
Mehta, G.1
Ferreira, V.P.2
Skerka, C.3
Zipfel, P.F.4
Banda, N.K.5
-
66
-
-
80052398914
-
Murine antithymocyte globulin T-cell depletion is mediated predominantly by macrophages, but the Fas/FasL pathway selectively targets regulatory T cells
-
Neff, K. S., Richards, S. M., Williams, J. M., Garman, R. D. & Ruzek, M. C. Murine antithymocyte globulin T-cell depletion is mediated predominantly by macrophages, but the Fas/FasL pathway selectively targets regulatory T cells. Transplantation 92, 523-528 (2011).
-
(2011)
Transplantation
, vol.92
, pp. 523-528
-
-
Neff, K.S.1
Richards, S.M.2
Williams, J.M.3
Garman, R.D.4
Ruzek, M.C.5
-
67
-
-
70449392430
-
Islet lymphocyte subsets in male and female NOD mice are qualitatively similar but quantitatively distinct
-
Young, E. F., Hess, P. R., Arnold, L. W., Tisch, R. & Frelinger, J. A. Islet lymphocyte subsets in male and female NOD mice are qualitatively similar but quantitatively distinct. Autoimmunity 42, 678-691 (2009).
-
(2009)
Autoimmunity
, vol.42
, pp. 678-691
-
-
Young, E.F.1
Hess, P.R.2
Arnold, L.W.3
Tisch, R.4
Frelinger, J.A.5
-
68
-
-
0842343422
-
A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8
-
Taylor, J. A. et al. A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8. J. Immunol. 172, 2651-2658 (2004).
-
(2004)
J. Immunol.
, vol.172
, pp. 2651-2658
-
-
Taylor, J.A.1
-
69
-
-
77949872804
-
Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes
-
Mohan, J. F. et al. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat. Immunol. 11, 350-354 (2010).
-
(2010)
Nat. Immunol.
, vol.11
, pp. 350-354
-
-
Mohan, J.F.1
-
70
-
-
84872316562
-
Recognition of self and altered self by T cells in autoimmunity and allergy
-
Yin, L. et al. Recognition of self and altered self by T cells in autoimmunity and allergy. Protein Cell 4, 8-16 (2013).
-
(2013)
Protein Cell
, vol.4
, pp. 8-16
-
-
Yin, L.1
-
71
-
-
84892166628
-
The repertoires of peptides presented by MHC-II in the thymus and in peripheral tissue: A clue for autoimmunity Front
-
Collado, J. A., Guitart, C., Ciudad, M. T., Alvarez, I. & Jaraquemada, D. The repertoires of peptides presented by MHC-II in the thymus and in peripheral tissue: a clue for autoimmunity Front. Immunol. 4, 442 (2013).
-
(2013)
Immunol.
, vol.4
, Issue.442
-
-
Collado, J.A.1
Guitart, C.2
Ciudad, M.T.3
Alvarez, I.4
Jaraquemada, D.5
-
72
-
-
0033566743
-
Insulin in oral immune tolerance: A one-amino acid change in the B chain makes the difference
-
Homann, D., Dyrberg, T., Petersen, J., Oldstone, M. B. & von Herrath, M. G. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J. Immunol. 163, 1833-1838 (1999).
-
(1999)
J. Immunol.
, vol.163
, pp. 1833-1838
-
-
Homann, D.1
Dyrberg, T.2
Petersen, J.3
Oldstone, M.B.4
Von Herrath, M.G.5
-
73
-
-
18144391496
-
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1
-
Skyler, J. S. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28, 1068-1076 (2005).
-
(2005)
Diabetes Care
, vol.28
, pp. 1068-1076
-
-
Skyler, J.S.1
-
74
-
-
0029944533
-
CD28/B7 system of T cell costimulation
-
Lenschow, D. J., Walunas, T. L. & Bluestone, J. A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
-
(1996)
Annu. Rev. Immunol.
, vol.14
, pp. 233-258
-
-
Lenschow, D.J.1
Walunas, T.L.2
Bluestone, J.A.3
-
75
-
-
77951922471
-
Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice
-
Brauner, H. et al. Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J. Immunol. 184, 2272-2280 (2010).
-
(2010)
J. Immunol.
, vol.184
, pp. 2272-2280
-
-
Brauner, H.1
-
76
-
-
84856825977
-
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients
-
Coppieters, K. T. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209, 51-60 (2012).
-
(2012)
J. Exp. Med.
, vol.209
, pp. 51-60
-
-
Coppieters, K.T.1
-
77
-
-
58149299735
-
Analysis of islet inflammation in human type 1 diabetes
-
Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K. & Morgan, N. G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155, 173-181 (2009).
-
(2009)
Clin. Exp. Immunol.
, vol.155
, pp. 173-181
-
-
Willcox, A.1
Richardson, S.J.2
Bone, A.J.3
Foulis, A.K.4
Morgan, N.G.5
-
78
-
-
84864381301
-
Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data
-
Greenbaum, C. J. et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61, 2066-2073 (2012).
-
(2012)
Diabetes
, vol.61
, pp. 2066-2073
-
-
Greenbaum, C.J.1
-
79
-
-
33845523340
-
Effects of autoimmunity and immune therapy on-cell turnover in type 1 diabetes
-
Sherry, N. A. et al. Effects of autoimmunity and immune therapy on-cell turnover in type 1 diabetes. Diabetes 55, 3238-3245 (2006).
-
(2006)
Diabetes
, vol.55
, pp. 3238-3245
-
-
Sherry, N.A.1
-
80
-
-
80755168884
-
Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies
-
Serreze, D. V. et al. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes 60, 2914-2921 (2011).
-
(2011)
Diabetes
, vol.60
, pp. 2914-2921
-
-
Serreze, D.V.1
-
81
-
-
55849136929
-
Curative and cell regenerative effects of 1-antitrypsin treatment in autoimmune diabetic NOD mice
-
Koulmanda, M. et al. Curative and cell regenerative effects of 1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl Acad. Sci. USA 105, 16242-16247 (2008).
-
(2008)
Proc. Natl Acad. Sci. USA
, vol.105
, pp. 16242-16247
-
-
Koulmanda, M.1
-
82
-
-
3042737844
-
Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4
-
Ogawa, N., List, J. F., Habener, J. F. & Maki, T., Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53, 1700-1705 (2004).
-
(2004)
Diabetes
, vol.53
, pp. 1700-1705
-
-
Ogawa, N.1
List, J.F.2
Habener, J.F.3
Maki, T.4
-
83
-
-
79960714565
-
Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice
-
Suarez-Pinzon, W. L. & Rabinovitch, A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice. Cell Transplant. 20, 1343-1349 (2011).
-
(2011)
Cell Transplant.
, vol.20
, pp. 1343-1349
-
-
Suarez-Pinzon, W.L.1
Rabinovitch, A.2
-
84
-
-
58149348476
-
Cell mass and type 1 diabetes: Going going gone
-
Akirav, E., Kushner, J. A. & Herold, K. C.-cell mass and type 1 diabetes: going, going, gone Diabetes 57, 2883-2888 (2008).
-
(2008)
Diabetes
, vol.57
, pp. 2883-2888
-
-
Akirav, E.1
Kushner, J.A.2
Herold, K.C.3
-
85
-
-
33750583959
-
Sirolimus is associated with reduced islet engraftment and impaired-cell function
-
Zhang, N. et al. Sirolimus is associated with reduced islet engraftment and impaired-cell function. Diabetes 55, 2429-2436 (2006).
-
(2006)
Diabetes
, vol.55
, pp. 2429-2436
-
-
Zhang, N.1
-
86
-
-
78049320362
-
Residual insulin production and pancreatic-cell turnover after 50 years of diabetes: Joslin Medalist Study
-
Keenan, H. A. et al. Residual insulin production and pancreatic-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59, 2846-2853 (2010).
-
(2010)
Diabetes
, vol.59
, pp. 2846-2853
-
-
Keenan, H.A.1
-
87
-
-
9144268894
-
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve-cell function: Report of an ADA workshop
-
21-22 October 2001
-
Palmer, J. P. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53, 250-264 (2004).
-
(2004)
Diabetes
, vol.53
, pp. 250-264
-
-
Palmer, J.P.1
-
88
-
-
80053434203
-
Rituximab selectively suppresses specific islet antibodies
-
Yu, L. et al. Rituximab selectively suppresses specific islet antibodies. Diabetes 60, 2560-2565 (2011).
-
(2011)
Diabetes
, vol.60
, pp. 2560-2565
-
-
Yu, L.1
-
89
-
-
40449086665
-
Dose translation from animal to human studies revisited
-
Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659-661 (2008).
-
(2008)
FASEB J.
, vol.22
, pp. 659-661
-
-
Reagan-Shaw, S.1
Nihal, M.2
Ahmad, N.3
-
90
-
-
82755197361
-
Detection of cell death in diabetes using differentially methylated circulating DNA
-
Akirav, E. M. et al. Detection of cell death in diabetes using differentially methylated circulating DNA. Proc. Natl Acad. Sci. USA 108, 19018-19023 (2011).
-
(2011)
Proc. Natl Acad. Sci. USA
, vol.108
, pp. 19018-19023
-
-
Akirav, E.M.1
-
91
-
-
79551715405
-
Human CD3 transgenic mice: Preclinical testing of antibodies promoting immune tolerance
-
Kuhn, C. et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci. Transl Med. 3, 68ra10 (2011).
-
(2011)
Sci. Transl Med.
, vol.3
, pp. 68-10
-
-
Kuhn, C.1
-
92
-
-
77956384921
-
Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2r null Ins2Akita mice
-
Brehm, M. A. et al. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2r null Ins2Akita mice. Diabetes 59, 2265-2270 (2010).
-
(2010)
Diabetes
, vol.59
, pp. 2265-2270
-
-
Brehm, M.A.1
-
93
-
-
84856274206
-
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients
-
Waldron-Lynch, F. et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl Med. 4, 118ra12 (2012).
-
(2012)
Sci. Transl Med.
, vol.4
, pp. 118-212
-
-
Waldron-Lynch, F.1
-
94
-
-
84904251418
-
Humanized mice as a model for aberrant responses in human T cell immunotherapy
-
Vudattu, N. K. et al. Humanized mice as a model for aberrant responses in human T cell immunotherapy. J. Immunol. 193, 587-596 (2014).
-
(2014)
J. Immunol.
, vol.193
, pp. 587-596
-
-
Vudattu, N.K.1
-
95
-
-
84899104487
-
A humanized mouse model of autoimmune insulitis
-
Viehmann Milam, A. A. et al. A humanized mouse model of autoimmune insulitis. Diabetes 63, 1712-1724 (2014).
-
(2014)
Diabetes
, vol.63
, pp. 1712-1724
-
-
Viehmann Milam, A.A.1
-
96
-
-
0029928590
-
Active suppression of diabetes after oral administration of insulin is determined by antigen dosage
-
Bergerot, I., Fabien, N., Mayer, A. & Thivolet, C. Active suppression of diabetes after oral administration of insulin is determined by antigen dosage. Ann. NY Acad. Sci. 13, 362-367 (1996).
-
(1996)
Ann. NY Acad. Sci.
, vol.13
, pp. 362-367
-
-
Bergerot, I.1
Fabien, N.2
Mayer, A.3
Thivolet, C.4
-
97
-
-
17444437590
-
Oral insulin administration and residual (-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial
-
Chaillous, L. et al. Oral insulin administration and residual (-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 356, 545-549 (2000).
-
(2000)
Lancet
, vol.356
, pp. 545-549
-
-
Chaillous, L.1
-
98
-
-
0030805783
-
Oral insulin for diabetes prevention in NOD mice: Potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant
-
Hartmann, B., Bellmann, K., Ghiea, I., Kleemann, R. & Kolb, H. Oral insulin for diabetes prevention in NOD mice: potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant. Diabetologia 40, 902-909 (1997).
-
(1997)
Diabetologia
, vol.40
, pp. 902-909
-
-
Hartmann, B.1
Bellmann, K.2
Ghiea, I.3
Kleemann, R.4
Kolb, H.5
-
99
-
-
77956257716
-
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
-
Grinberg-Bleyer, Y. et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871-1878 (2010).
-
(2010)
J. Exp. Med.
, vol.207
, pp. 1871-1878
-
-
Grinberg-Bleyer, Y.1
-
100
-
-
34548751075
-
Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts
-
Koulmanda, M. et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc. Natl Acad. Sci. USA 104, 13074-13079 (2007).
-
(2007)
Proc. Natl Acad. Sci. USA
, vol.104
, pp. 13074-13079
-
-
Koulmanda, M.1
-
101
-
-
43049174722
-
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
-
Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
-
(2008)
Immunity
, vol.28
, pp. 687-697
-
-
Tang, Q.1
-
102
-
-
58149357117
-
Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice
-
Suarez-Pinzon, W. L. et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57, 3281-3288 (2008).
-
(2008)
Diabetes
, vol.57
, pp. 3281-3288
-
-
Suarez-Pinzon, W.L.1
|